Kvasnicka T
III. interní klinika 1. Iékarské fakulty UK a VFN Praha.
Vnitr Lek. 2008 Feb;54(2):191-4.
The endocannabinoid system is an endogenous signaling system that plays a role in the regulation of energy homeostasis and lipid and glucose metabolism-all of which can influence cardiometabolic risk. The endocannabinoid system appears to be a promising novel mechanistic pathway that modulates important aspects afcardiovascular and metabolic function. The endocannabinoid system is normally a silent physiologic system that becomes transiently activated, that is, only when needed. Evidence suggests that the endocannabinoid system is tonically overactive in human obesity and in animal models of genetic and diet-induced obesity. However, there is evidence in studies that the ECS is tonically overactivated in obesity, although it remains unclear whether overactivation of the ECS precedes or is consequent to expression of the obese phenotype. Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce smoking, body weight and improve and improves the profile of several metabolic risk factors in high-risk patients.
内源性大麻素系统是一种内源性信号系统,在能量稳态以及脂质和葡萄糖代谢的调节中发挥作用,而所有这些都可能影响心脏代谢风险。内源性大麻素系统似乎是一条有前景的新型机制途径,可调节心血管和代谢功能的重要方面。内源性大麻素系统通常是一个沉默的生理系统,仅在需要时才会短暂激活。有证据表明,内源性大麻素系统在人类肥胖以及遗传和饮食诱导的肥胖动物模型中持续过度活跃。然而,研究中有证据表明,尽管尚不清楚内源性大麻素系统的过度激活是先于肥胖表型的表达还是肥胖表型表达的结果,但该系统在肥胖中持续过度激活。利莫那班是一种选择性大麻素-1受体(CB1)阻滞剂,已被证明可减少高危患者的吸烟量、降低体重并改善多种代谢危险因素。